Antileukemic activity of sulfonamide conjugates of arabinosylcytosine

Experimental Oncology

Volumn 28, Issue 4, 2006, Pages 293-298

  Novotny, L ^a   Phillips, O A ^a   Rauko, P ^b   Miadokova, E ^c  

^a KUWAIT UNIVERSITY   (Kuwait)

^b CANCER RESEARCH INSTITUTE   (Slovakia)

^c Physics and Informatics   (Slovakia)

Author keywords

Antileukemic activity; Arabinosylcytosine; Conjugates; Cytarabine; Leukemia L1210; Sulfanilamide

Indexed keywords

4 AMINO N [1 (3,4 DIHYDROXY 5 HYDROXYMETHYLTETRAHYDROFURAN 2 YL) 4 IMINO 1,4 DIHYDROPYRIMIDIN 2 YL]BENZENESULFONAMIDE; 8 (4 AMINOBENZENESULFONYL) 5 IMINO 13 OXA 2,6,8 TRIAZATRICYCLO[8.2.1.02,7]TRIDECA 3,6 DIENE 11,12 DIOL; CYTARABINE; CYTARABINE DERIVATIVE; CYTIDINE DERIVATIVE; SULFANILAMIDE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; IC 50; INFRARED SPECTROMETRY; LEUKEMIA; LEUKEMIA L 1210; MALE; MOUSE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; SPECTROPHOTOMETRY; TREATMENT OUTCOME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CYTARABINE; FEMALE; LEUKEMIA; MALE; MICE; SULFONAMIDES;

EID: 33846862052     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, Greer J, Briel J, Smith BD, Gore SD, Tidwell ML, Ross DD, Wright JJ, Colevas AD, Bauer KS. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 2005; 11: 8403-12.
2. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Zeller B, Gustafsson G. Nordic Society of Pediatric Hematology and Oncology (NOPHO); AML Study Group Nordic Society of Pediatric Hematology and Oncology (NOPHO); AML Study Group. Long-term results in children with AML: NOPHO-AML Study Group - report of three consecutive trials. Leukemia 2005; 19: 2090-100.
3. Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. Jpn J Clin Oncol 2005; 35: 612-6.
4. Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S; EORTC Leukemia Cooperative Group. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005; 19: 1929-33.
5. Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ; Children's Cancer Group. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005; 19: 2054-62.
6. Robak T, Korycka A, Kasznicki M, Wrzesien-Kus A, Smolewski P. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications. Curr Cancer Drug Targets 2005; 5: 421-44.
7. Nakayama T, Sakamoto S, Sassa S, Suzuki S, Kudo H, Nagasawa H. Paradoxical effect of cytosine arabinoside on mouse leukemia cell line L1210 cells. Anticancer Res 2005; 25: 157-60.
8. Krett NL, Ayres M, Nabhan C, Ma C, Nowak B, Nawrocki S, Rosen ST, Gandhi V. In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol 2004; 54: 113-21.
9. Gandhi V, Xu YZ, Estey E. Accumulation of arabinosyluracil 5′-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin Cancer Res 1998; 4: 1719-26.
10. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J. Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998; 26: 421-5.
11. Burk M, Heyll A, Arning M, Volmer M, Fartash K, Schneider W. Pharmacokinetics of high-dose cytarabine and its deamination product - a reappraisal. Leuk Lymphoma 1997; 27: 321-7.
12. Stankovicova M, Rauko P, Bachrata M, Blesova M, Sveda P. In vitro antileukemic activity and chemical transformation of the 5′-chloro-5′-deoxy derivative of cyclocytidine. Neoplasma 1995; 42: 255-8.
13. Saiko P, Horvath Z, Bauer W, Hoechtl T, Grusch M, Krupitza G, Rauko P, Mader RM, Jaeger W, Schott H, Novotny L, Fritzer-Szekeres M, Szekeres T. In vitro and in vivo antitumor activity of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine. Int J Oncol 2004; 25: 357-64.
14. Erion MD, van Poelje PD, Mackenna DA, Colby TJ, Montag AC, Fujitaki JM, Linemeyer DL, Bullougti DA. Liver-targeted drug delivery using HepDirect prodrugs. J Pharmacol Exp Ther 2005; 312: 554-60.
15. Lee KH, Jung YJ, Hong CI, Cho MH, Bai DH, Kim SH, Choi KY, Yu JH, Kim CM. Activation of protein kinase C by 1-beta-D-arabinofuranosylcytosine conjugates of phospholipid. Int J Oncol 2004; 24: 193-9.
16. Alexander RL, Morris-Natschke SL, Ishaq KS, Fleming RA, Kucera GL. Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3- phosphatidic acid conjugates with gemcitabine and cytosine arabinoside. J Med Chem 2003; 46: 4205-8.
17. Cavallaro G, Pitarresi G, Licciardi M, Giammona G. Polymeric prodrug for release of an antitumoral agent by specific enzymes. Bioconjug Chem 2001; 12: 143-51.
18. Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, Sorg UR, Seeber S, Moritz T, Flasshove M. Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia 2005; 19: 2281-8.
19. Lofgren C, Albertioni F, Paul C. High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML. Ther Drug Monit 2005; 27: 641-6.
20. Han T, Fernandez M, Chou TC, Agarwal RP. Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine- resistant human lymphoid cells. J Cancer Res Clin Oncol 2005; 131: 609-16.
21. Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 2005; 93: 1388-94.
22. Braess J, Fiegl M, Lorenz I, Waxenberger K, Hiddemann W. Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia. Clin Cancer Res 2005; 11: 7415-25.
23. Puccetti L, Fasolis G, Cecchi A, Winum JY, Gamberi A, Montero JL, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating thioureido-sulfanilyl scaffolds. Bioorg Med Chem Lett 2005; 15: 2359-64.
24. Novotny L, Hrebabecky H, Beranek J. Synthesis of the sulfonamido derivatives of arabinonucleosides. Collect Czech Chem Commun 1985; 50: 383-92.
25. Schwendener R, Schott H. Lipophilic arabinofuranosyl cytosine derivatives in liposomes. Methods Enzymol 2005; 391: 58-70.
26. Liu X, Guo Y, Li Y, Jiang Y, Chubb S, Azuma A, Huang P, Matsuda A, Hittelman W, Plunkett W. Molecular basis for G2 arrest induced by 2′-C-cyano-2′-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res 2005; 65: 6874-81.
27. Richardson KA, Vega TP, Richardson FC Moore CL, Rohloff JC, Tomkinson B, Bendele RA, Kuchta RD. Polymerization of the triphosphates of AraC, 2′,2′-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase. Biochem Pharmacol 2004; 68: 2337-46.
28. Schiavon O, Pasut G, Moro S, Orsolini P, Guiotto A, Veronese FM. PEG-Ara-C conjugates for controlled release. Eur J Med Chem 2004; 39: 123-33.
29. Mohan R, Banerjee M, Ray A, Manna T, Wilson L, Owa T, Bhattacbaryya B, Panda D. Antimitotic sulfonamides inhibit microtubule assembly dynamics and cancer cell proliferation. Biochemistry 2006; 45: 5440-49.
30. Supuran CT. Indisulam: an anticancer sulfonamide in clinical development. Expert Opin Investig Drugs 2003; 12: 283-87.
31. Zhang GS, Liu DS, Dai CW, Li RJ. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol 2006; 81: 242-55.
32. Chow LW, Loo WT, Wai CC, Lui EL, Zhu L, Toi M. Study of COX-2, Ki67, and p53 expression to predict effectiveness of 5-flurouracil, epirubicin and cyclophosphamide with celecoxib treatment in breast cancer patients. Biomed Pharmacother 2005; 59: S298-301.
33. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004; 19: 199-229.
34. Scozzafava A, Owa T, Mastrolorenzo A, Supuran CT. Anticancer and antiviral sulfonamides. Curr Med Chem 2003; 10: 925-53.
35. Rauko P, Bauer W, Horvath Z, Hochtl T, Saiko P, Karl D, Schott H, Fritzer-Szekeres M, Novotny L, Szekeres T. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice. Anticancer Res 2003; 23: 3841-46.